Experimental cancer drug trial halted early
NCT ID NCT05462873
First seen Feb 22, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This early-phase study tested a new drug called QEQ278 in 30 adults with advanced lung, kidney, esophageal, or head and neck cancers that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital Dept. of Mass General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Paris, 75231, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
University of California LA
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.